Details of the Drug Combination

General Information of Drug Combination (ID: DCD2IBQ)

Drug Combination Name
Insulin-lispro Linagliptin
Indication
Disease Entry Status REF
Type 2 Diabetes Mellitus Phase 4 [1]
Component Drugs Insulin-lispro   DM4O90W Linagliptin   DMWFJTR
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Insulin-lispro
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [2]
Non-insulin dependent diabetes 5A11 Approved [3]
Type-1 diabetes 5A10 Approved [4]
Insulin-lispro Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Insulin receptor (INSR) TTCBFJO INSR_HUMAN Binder [9]
------------------------------------------------------------------------------------
Indication(s) of Linagliptin
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [5]
Type 2 diabetes 5A11 Approved [6]
Type-2 diabetes 5A11 Approved [7]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [8]
Linagliptin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [10]
HUMAN dipeptidyl peptidase 4 (DPP-4) TTF928K DPP4_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Linagliptin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03320031) A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006 Jul;12(7):RA130-47. Epub 2006 Jun 28.
4 Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172.
5 Linagliptin FDA Label
6 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 208026
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
8 ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
9 Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
10 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
11 DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
12 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.